-
-
-
-
-
-
-
Rogers (ROG) Tops Q3 EPS by 21c ; Offers Guidance
-
-
-
-
-
-
-
FDA rejects Genentech's Columvi combination for lymphoma treatment
-
-
-
-
-
-
-
Pharma stocks slide after Trump signals tariffs on sector
-
-
-
-
-
-
-
Rogers (ROG) Tops Q3 EPS by 13c, Misses on Revenue; Offers Q4 Guidance
-
-
-
-
-
414,166 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

